Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

The Election Committee of Vitrolife, which was appointed in accordance with the
resolution of the Annual General Meeting on May 5, 2015, consists of:

Patrik Tigerschiöld, Chairman of the Election Committee, representing Bure
Equity AB
Niels Jacobsen, representing William Demant Invest A/S
Thomas Olausson
Carsten Browall, Chairman of the Board

The Election Committee proposes the following to the Annual General Meeting of
Vitrolife that will take place on Thursday April 28, 2016:

-  that the Chairman of the meeting shall be Carsten Browall.

-  that the members of the Board shall be six in number.

-  that the Board remuneration shall be SEK 1,615,000, of which SEK 500,000 to
the Chairman of the Board, SEK 175,000 to each of the other members of the
Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the
Chairman of the Remuneration Committee and SEK 30,000 to the other members of
these committees. The proposal equals an increase of SEK 175,000 of the total
amount compared to the previous year.

-  re-election of the Board members Fredrik Mattsson, Tord Lendau, Barbro
Fridén, Pia Marions, Carsten Browall and Jón Sigurdsson.

-  re-election of Carsten Browall as Chairman of the Board.

- that a new Election Committee be set up for the Annual General Meeting of
2017. It is proposed that the Election Committee is appointed in the same way as
previously, whereby the Chairman of the Board contacts the three largest
registered shareholders or otherwise known owners at the end of the third
quarter of 2016 and asks them to appoint one member each. The three members who
are appointed and the Chairman of the Board constitute the Election Committee.
The Election Committee appoints a Chairman internally.
Contact:
Patrik Tigerschiöld, Chairman of the Election Committee, phone 46 8 614 00 20
Carsten Browall, Chairman of the Board, phone 46 70 255 65 32

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
21, 2016 at 11:00 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
about 110 markets. The company is headquartered in Gothenburg, Sweden, and there
are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan,
Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid
Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/